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Abstract
Background: The German Network of Disorders of Sex Development (DSD)/Intersexuality
carried out a large scale clinical evaluation study on quality of life, gender identity, treatment
satisfaction, coping, and problems associated with diagnoses and therapies in individuals with
disorders of sex development (DSD). DSD are a heterogeneous group of various genetic disorders
of sex determination or sex differentiation, all of which are rare conditions. In about half of all cases
the molecular genetic diagnosis is unknown and diagnosis rests on clinical features.
Methods and design: The multi-centre clinical evaluation study includes short-term follow-up in
some and cross-sectional assessments in all age and diagnostic groups fitting the criteria of DSD.
Recruitment was from January 2005 until December 2007 in whole Germany and, additionally, in
2007 in Austria and German-speaking Switzerland. The study consists of a psychosocial inquiry for
children, adolescents and their parents, and adults with standardized instruments and the collection
of DSD-specific medical data by the attending physician. The main goal was the description of
clinical outcomes and the health-care situation of individuals with DSD using a broad generic
definition of DSD including all conditions with a mismatch of chromosomal, gonadal and
phenotypical sex. 439 children and adolescents, their parents and adults with DSD participated.
Discussion: The clinical evaluation study represents the most comprehensive study in this clinical
field. The paper discusses the study protocol, the data management and data quality as well as the
classification used, and it describes the study population. Given the lack of large datasets in rare
conditions such as DSD and often biased results from small scale clinical case series, the study aims
to generate concrete hypotheses for evidence-based guidelines, which should be tested in further
studies.
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Background
Disorders of sex development (DSD) are a heterogeneous
group of rare conditions. A German epidemiological
study estimates a rate of 2.2/10 000 cases with ambiguous
genitalia at birth at minimum [1]. Not included were con-
ditions which are not obvious at birth but are diagnosed
later in childhood or adolescence. Most specific condi-
tions occur at a rate of 1:100.000 births or less. DSD are
defined as congenital conditions with a mismatch of chro-
mosomal, gonadal and phenotypical sex. A new nomen-
clature and classification has been suggested, delineating
DSD with 46, XX karyotype and signs of androgen excess,
namely congenital adrenal hyperplasia (CAH), and those
with 46, XY karyotype and signs of complete or partial
lack of virilization. The latter include partial and/or com-
plete androgen insensitivity, complete and partial
gonadal dysgenesis, and disorders of androgen hormone
synthesis (e.g. 5α-reductase deficiency, 17β-hydroxyster-
oid-dehydrogenase deficiency). Sex chromosome anoma-
lies such as Turner syndrome, Klinefelter-Syndrome,
mixed gonadal dysgenesis, mosaics may be classified as
DSD [2], but were not included in this study.
The rareness of a condition creates a serious challenge for
research and patient care. Among approximately 30.000
diseases 5–7.000 are considered »rare« conditions with
prevalence less than 1:2.000. Although rare, millions of
people are affected worldwide but many lack access to
specialized caregivers. The majority of conditions require
extensive diagnostic procedures, ongoing symptomatic
therapy and psychosocial support. Specific treatments
often are not available and studies to promote evidence
based treatment strategies are hampered by the heteroge-
neity of causes and clinical presentation, small numbers
of individuals being treated in each centre, lack of incen-
tives for the pharmaceutical companies to invest in
research, and the lack of experience of the professionals
involved. Therefore, the German Ministry of Education
and Science (BMBF) has been funding ten disease-specific
networks for rare diseases since 2003. Aim of this initia-
tive is to promote national networks concerning research,
specialized clinical and diagnostic centers and self-help
and parent organizations.
One of the funded networks is the German Network DSD/
Intersexuality, which started its work in October 2003.
The network includes more than 40 institutions, 150 pro-
fessionals and self-help groups in Germany for coopera-
tion and will respond to the need for greater scientific
knowledge in etiology and prognosis of various DSD con-
ditions and improved health care. Overall goals were to
develop guidelines for clinical care and support clinicians
in coordination and collaboration, provide counseling,
develop information and educational material for people
with DSD, increase public knowledge about of the biol-
ogy of sex development, and encourage respectful and
appropriate communications with people affected. Cen-
tral element of the network is the multi-centre clinical
evaluation study. Part of the motivation for the research
program was to develop appropriate methodologies to
conduct clinical studies in rare conditions. Issues of heter-
ogeneity of data, large variation among centers, small
sample sizes in subgroups, age and gender appropriate-
ness, validity of instruments, and interdisciplinary collab-
oration have to be addressed to be able to ensure the
quality of data and develop analytical methods.
The aim of this paper is to describe and explain the study
design, to characterize the study population, and to assess
the data quality. We will describe specific critical issues for
studies in the field of DSD in section 2. The special aims
of the present study are presented in Section 3. Section 4
is directed to the study design and is followed by a speci-
fication of the data management. The study population is
described in Section 6. In Section 7, the data quality is
assessed. A discussion of the chances and limitations of
the study completes the paper.
1. General problems of outcome studies in Disorders of Sex 
Development
Evidence-based treatment of patients with DSD is chal-
lenged by a dearth of clinical longitudinal outcome stud-
ies. Given the rarity of the condition, the heterogeneity of
the clinical symptoms and variation in both surgical and
medical treatments, evidence based guidelines are lacking
beyond expert recommendations [3]. Therefore parents'
and clinicians' decisions are often based on the clinicians'
expertise, expert opinion and not on adequate data [4].
Reviews and studies about long-term outcomes concern-
ing DSD mainly focus on psychosexual and surgical out-
comes; e.g. [5-9]; especially in CAH; e.g. [10-25].
Obviously psychosexual aspects are important outcome
parameters in context of DSD. Nevertheless, there are
more criteria to evaluate treatment in individuals with
DSD. There are few studies with such a broader spectrum
of outcomes measured such as health related quality of
life or mental health [26-36]. However in the majority of
these studies, only special diagnostic groups are investi-
gated and solely patients of a single medical institution or
participants recruited by patient organizations have been
inquired. Resulting problems are small sample sizes and
recruitment biases. A more generic definition of DSD is
important because condition specific studies will exclude
people from research, as they do not fit the narrow catego-
ries (e.g. syndromal disorders, disorders of unknown eti-
ology). Another problem is the missing comparability
because every study employs other methods. Most of the
DSD-studies could be classified as case series. Because of
recruitment problems in context of rare disorders there are
only poor quality cohort and case-control studies. Out-BMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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come studies concerning DSD are hampered by several
problems (modified from Mazur) [7]:
1. Lack of accurate diagnosis
The best choice is a molecular genetic characterization for
inclusion criteria. However, in 50% of the cases the
molecular diagnosis is missing. To integrate these patients
in clinical outcome studies, strict clinical inclusion criteria
are necessary.
2. Selection bias
There is a selection bias when patients are recruited by
former and actual care providers as well as by self-help
groups. In many studies no information about the
patients who refused to participate is available. Samples
recruited by advocacy groups are not representative for the
total population, because many patients are not organized
in these groups. Patient registers with inclusion of cases at
the time of diagnoses should greatly help to ensure proper
representation, but they are only established in a few
regions in Europe [37].
3. Missing independence of care provider and researcher
Studies conducted by the clinical care provider may have
increase responses of social desirability. Because of the
sensibility of the nature of the subject, independent
trained research teams should conduct these studies and
assure that the personal information is not transferred to
the care providers.
4. Small sample sizes
One of the reasons is that many diagnoses are extremely
rare. A broader recruitment strategy using strict clinical
inclusion criteria such as the above mentioned generic
DSD-definition [2] allows studies with larger samples.
5. Lacking control groups
The described broad recruitment also opens the door for
comparisons of different DSD-groups (e.g. girls/women
with CAH vs. girls/women with partial androgen effects
vs. girls/women with no androgen effects). Furthermore,
patients with other chronic disorders and controls from
the general public must be interviewed with the same bat-
tery of instruments where applicable.
6. Lack of standardized instruments
There is a lack of standardized instruments to measure dis-
ease-specific quality of life and other subjective outcomes.
Because of comparability, it seems necessary to establish
batteries of instruments that will be used by different
groups and to use the same descriptive terminology.
The described problems show that the rareness of disor-
ders of sex development requires more national and inter-
national cooperation to increase sample sizes and to get
high-quality outcome data. The German-wide outcome
study was designed to overcome at least some of the
described problems.
2. Overall purpose
The clinical evaluation study represents the most compre-
hensive study in this clinical field and includes short-term
follow-up in some and cross-sectional assessments in all
age and diagnostic groups. In preparation of the study, a
large multi-professional research team discussed the
inclusion of girls and women with CAH in a DSD-study.
Many clinicians considered CAH as a metabolic disorder
of the adrenal gland avoiding to address psychosexual
issues in the care of their patients. However due to the
ambiguous genitalia, medical, surgical and psychosocial
problems may be similar as in patients with 46, XY karyo-
type and DSD; this opinion was confirmed by the inclu-
sion of CAH in the classification of the consensus group
later on [2]. The main outcomes in the study include the
following parameters: phenotype of the external and
internal genitalia, physical health including additional
health problems, fertility, and sexual function in adults;
social and psychosexual adjustment, mental health, qual-
ity of life, and social participation, social support, and
coping. The inclusion of different etiological groups is
important to generate hypotheses regarding the relevance
of genetic, hormonal, psychological and social influence
for the main outcomes. Typical treatment sequences and
decisions for special interventions and treatment satisfac-
tion are explored as potential co-factors. The main goal of
the study is to generate concrete hypotheses for evidence-
based guidelines, which should be tested in further stud-
ies. Until now, the scientific knowledge is not sufficient to
generate a-priori hypotheses.
Methods and design
1. Design, instruments, and logistics
Inclusion/exclusion criteria
Inclusion criteria of the study followed the above men-
tioned generic definition of DSD as a discrepancy of chro-
mosomal, gonadal and phenotypical sex. We included
both participants with a confirmed diagnosis of DSD (by
molecular genetic testing, laboratory results, or histology)
or a clinical diagnosis by a physician. Excluded were indi-
viduals with Klinefelter- or Ullrich-Turner-Syndrome,
severe psychiatric comorbidity and mental disabilities.
Included were all individuals meeting the mentioned cri-
teria and living in Germany or German-speaking Switzer-
land or Austria.
Study design
The design was dependent on the allocation to subgroups
related to age and time since first diagnosis:BMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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a) Newborns, children and adolescents up to the age of 16
with a new diagnosis of a DSD within the last 6 months
and their parents were contacted twice. After the baseline
visit, there was a follow-up interview after 12 months
(cohort).
b) Children and adolescents up to the age of 16 with a
DSD prior 6 months before the study and their parents
had only one interview (cross-sectional).
c) Adults with DSD had also only one interview (cross-
sectional).
The sample size for this highly explorative study with a
widespread field of outcome parameters in a heterogene-
ous population was primarily planned under the aspect of
feasibility. Based on the available patients with DSD in
Germany and on their assumed high interest in this study,
we expected to include approximately 400 patients, which
is much more than in previous studies in the literature.
We concluded that the most relevant age groups would
then cover about 80 to 120 patients, so that different sub-
groups regarding classification by diagnosis or treatment
could attain a size of about 40. Such sample sizes enable
to detect, e.g., differences of about 5 to 7 in the physical
and mental sum score of the SF-36 (two-sided compari-
son of two groups, α = 0.05, standard deviation of about
10 and power of 80%), which is just a difference typical
for some severe chronic diseases.
Instruments
There are few condition-specific instruments for DSD. We
selected and developed different questionnaires after con-
sulting experts in the field and extensive review of the lit-
erature. The Clinical Evaluation Study consists of two
components:
1. Psychosocial inquiry for children, adolescents and their
parents, and adults conducted by psychologists with
standardized instruments during personal encounters:
The battery of instruments for the psychosocial inquiry
includes standardized and validated instruments in Ger-
man language where available. Instruments suitable but
not available in German have been translated. The trans-
lations were carried out according to international trans-
lation standards [38] with two separate backward and
forward professional translations. Because of specific vul-
nerabilities in individuals with DSD, some items were
modified slightly, e. g., replacing of the word "illness".
The standardized and evaluated instruments are related to
health-related quality of life, mental health, treatment sat-
isfaction, coping, parenting stress, social support, body
image, gender identity, and gender role behavior with dif-
ferent methods or specific formats for different age-groups
including proxy-versions for parents. Specific condition
related items were added in a self-constructed question-
naire. The self-constructed disease-specific DSD-question-
naires for parents, adolescents and adults cover major
aspects concerning DSD and have been developed in
cooperation with support groups and parent organiza-
tions (focus group discussions), and academic and medi-
cal experts. All DSD-questionnaires cover the domains
sociodemographic information, child's or own social life,
diagnostic procedures, medical and surgical interventions,
exposure to DSD and experiences. Adults and parents are
additionally asked about pregnancy and childbirth
whereas adolescent's and adult's questionnaires contain
items in context of partnership and sexuality. The adult
DSD-questionnaire contains 112 items, the parent version
106 and the adolescent version 53 items. Children aged 4
or above participated in the study, answering some stand-
ardized questionnaires. An overview of the instruments
used in the different age groups is given in Table 1. A more
detailed description of all questionnaires is given in the
additional file 1[39-58].
2. The Questionnaire "Medical Data" was to be completed
by the attending physician to document the medical his-
tory and diagnostic findings of each participant. The 64-
item questionnaire is composed of four main thematic
domains: pregnancy & delivery, diagnosis & initial find-
ings (Prader stages, severity of hypospadias, external &
internal genitalia, gonads, and genetics), therapeutic his-
tory (masculinizing & feminizing surgeries, surgical com-
plications, and hormonal treatment), current/last
findings (general health, external genitalia, Tanner stages,
pubertal development, diagnosis). The development was
assisted by a medical expert-group of network members.
The questionnaire was adopted in a consensus meeting.
The study design, patient information and questionnaires
battery were presented to and discussed with the Euro-
pean Scientific Advisory Board at a workshop at the ESPE
meeting in Basel in September 2004.
The study project management and the biometry group
met in May 2006 for an interim data analysis. All items of
non-standardized questionnaires were checked for miss-
ing data and plausibility. Implausible items as well as
such items having a very high missing rate have been
removed from the non-standardized questionnaires in
order to reduce the time effort and strain for the partici-
pants. One of the standardized instruments (coping in
children) was dismissed as respondents apparently did
not understand some of the questions and high rates of
missing data.
Ethics
Ethics approval was sought first from the medical ethic
committee at the University Lübeck. Subsequently ethicBMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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approvals were sought from the ethic review boards in the
other study centers. An essential requirement was to
develop and implement procedures to ensure data protec-
tion. Every participant received the same informed con-
sent sheets, including information about data security and
a waiver of consent to allow transmission of confidential
medical information from the physician. All adolescents,
patients and adults gave written consent to participation
and release of medical data. Children were verbally asked
to consent to participate after age-appropriate explana-
tions. Parents could decline the participation of their chil-
dren (4–12 years), but were allowed to participate
themselves.
Policies and methods on data analysis and publication of
results were discussed with co-investigators and partners
of the clinical study. Network partners and researchers
stating certain interests in subsets of the data may submit
written proposals on data analysis including objectives,
methods and anticipated results. After review, the scien-
tific board will permit access to all or subsets of the data
made anonymous, not permitting identification of per-
sonal data.
Recruitment
Recruitment started in December 2004 and interviews in
January 2005. Because of their specialization in DSD,
recruitment took place mainly in the study centers in
Lübeck (north), Magdeburg/Berlin (east), Essen/Bochum
(west) and Erlangen (south). Additionally, medical coop-
eration partners and self-help groups in Germany partici-
pated to encourage their patients/members to join the
study and to dispense the information flyer. In Austria
and Switzerland cooperation partners participated in St.
Gallen, Bern, Vienna, Linz and Innsbruck (starting Janu-
ary, 2007). In the preparation phase, widespread informa-
tion about the study was given to physicians via medical
journals, scientific meetings, the network-DSD-
homepage, personal communication and a newsletter
from the DSD-network. We expected to recruit 400 partic-
ipants between January 2005 and December 2007.
In case an individual was invited to participate in the
study but declined, we collected some basic information
(i.e. the recruiting study center and access to the study, age
group, assigned gender, diagnosis and the time of first
diagnosis of DSD), in order to perform a non-responder
analysis at the end of the study.
Study logistics
Following the initial contact, a telephone intake call took
place to explain the study, to explore the patient's interests
and willingness to participate in any or all parts of the
study and to arrange the realization of the interview. The
Table 1: Instruments used for different age groups. A detailed of the instruments is given in the additional file 1.
Instrument Parents Children Adol. Adults
Age (years) 0–0.5 0.5–3 4–7 8–12 13–16 4–7 8–12 13–16 >16
KINDL X X X X X X
SF-36 X
SDQ X X X X
BSI X
CHC-SUN X X X X X
CSQ-8 X
CODI X








Toy to keep XX
DSD-parents X X X X X
DSD-adults X
DSD-adolescents X
Medical data answered by attending physician
BI-1: Body Image Scale, BSI: Brief Symptom Inventory, CBAQ: Child Behavior and Attitudes Questionnaire, CHC-SUN: (Child Health Care – 
Satisfaction, Utilization and Needs, CODI: Coping questionnaire for children and adolescents, CSQ-8: Client satisfaction questionnaire, DSD: 
Disorder of Sex Development, FGI: Questionnaire of Gender Identity, FKSI: Frankfurt children's self-concept inventory, GRQ: Gender Role 
Questionnaire, GII: Gender Identity Interview, KINDL: Questionnaire for measuring health-related quality of life in children and adolescents, PSI: 
Parenting Stress Index, SDQ: Strengths and Health Questionnaire, SF-36: Health Survey, UGDS: Utrecht Gender Dysphoria ScaleBMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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study interviews took place at one of the study centers or
at participant's home, depending on preferences of the
participants. Data from individual patients have been col-
lected as written questionnaires. Although information
was collected as quantitative data in paper and pencil
inquiries with only few open questions, the interviews
always took place in personal attendance of one of the
trained interviewers who were all psychologists. Due to
the sensitive nature of the subjects and concerns about re-
activation of past traumatic experiences, the European sci-
entific advisory board of the study, had disapproved to
send questionnaires per mail. An attending physician
completed the questionnaire „medical data" with written
consent by the participant. The study centre psychologist
coded all study sheets according predefined coding
instructions, removed personal data and created an indi-
vidual identification number. After checking for missing
and implausible data, staff sent the completed study
sheets to Magdeburg for data entry.
2. Data management
The study data is kept in a Microsoft Access 2000 database
consisting of several tables organized as groups of ques-
tionnaires. One of the tables was for the first-contact tele-
phone call containing only data that were collected both
for participants and non-participants. A second identical
database was used for double entry. Both data bases are
stored on the institute's server at the University of Magde-
burg; routine backup was performed by the hospital's
computing centre. In addition, a regular backup on an
external disk kept separately in a secure place in another
room was made. Access to the data base and to the back-
ups was restricted to the staff directly included in the
study. The server was not accessible via the web.
The data of each participant were entered into the data-
base using Microsoft Access input forms. This included
also a second line data check. In case of incomplete and
obviously implausible data the data entry was suspended
and a feedback was given to both the central study centre
in Lübeck and the local study centers for further evalua-
tion and correction. After completion of the queries data
entry was continued. In order to ensure a high data qual-
ity, a second data entry was completed by another docu-
mentarian. In regular intervals the data bases for first and
second data entry were checked and matched using the
software SAS/PROC COMPARE.
For further statistical analysis, these tables were imported
in the statistical software SPSS.
Results
1. Description of the study population
General description
Overall 516 individuals were contacted for the study. Five
of them had to be excluded due to applicable exclusion
criteria – two with Turner syndrome, two with Klinefelter
syndrome and one individual with mental retardation. 72
individuals denied participation. Thus a total of 439 par-
ticipants were interviewed. This includes two children
who died during the study. One child (newborn) died
after the first visit and was lost for the follow-up visit,
another child (age group 4–7 years) died before the inter-
view, but the parents answered the DSD questionnaire.
Table 2 describes the study population with regard to the
recruiting study centre, access to recruitment, the sex of
rearing/recent gender, age groups, time of first diagnosis,
and diagnosis related inclusion criteria (categories in lat-
ter are not mutually exclusive). Participants and non-par-
ticipants are presented separately. Statistical analysis of
the non-participants follows in the next section on data
quality.
Most active participants (378) were recruited via the study
centers or approximately 60 cooperation partners of the
study. Forty participants were recruited by self-help
groups, 9 via internet. The proportion of self-referrals (i.e.,
recruited via self-help groups or internet) was larger in
adult participants (23/110) than in parents (26/329). Of
the 110 adult participants, 20 were active in self-help
groups.
Altogether, 142 different physicians completed the ques-
tionnaire "medical data". Six of them completed more
than ten and four of them more than 20 questionnaires.
Most of the physicians (80,1%) completed only one or
two questionnaires.
Classification of patients
The sample includes more than 30 different diagnoses as
stated in the "medical data" questionnaire. Twelve indi-
viduals have an unclassified diagnosis of DSD. 54 individ-
uals with the clinical diagnosis "severe hypospadia" with
unknown underlying disorder participated. According to
the treating physician, in 342 participants (77.9%; exclud-
ing the 54 patients with hypospadia) the final diagnosis
has been confirmed by genetic, laboratory, endoscopic or
other tests.
Most of these diagnoses occurred in very small numbers
limiting power for statistical analyses. To be able to group
patients, we decided to use a classification by karyotype,
signs of androgen effects (XY-DSD and XX-DSD as sug-
gested by the consensus statement of the ESPE/LWSPE
conference) and sex of rearing/recent gender (9 adults
stated to live neither in female nor male gender, in one
child there is no definite decision about sex of rearing.
Because of statistical reasons, they were integrated into the
classification system. The child was integrated in the DSD-
XY-P-F group because of her own declaration of being a
girl. The decision for the 9 adults was based on the officialBMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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status in the civil registries.), which combines the most
important aspects regarding physical condition, effects of
socialization and experiences of individuals with DSD
[32]. Sex of rearing is used for children and adolescents on
the basis of the parent's decision whereas the term recent
gender role is used for adolescents.
Subgroup 1 (DSD-XX-P-F)
Individuals with XX-karyotype and partial androgen
effects, reared as girls/living as women (n = 178). This
subgroup consists in great part of women with CAH, but
includes also few individuals with aromatase deficiency.
Subgroup 2 (DSD-XX-P-M)
Individuals with XX-karyotype and partial androgen
effects, reared as boys/living as males (n = 9). This
includes the diagnoses CAH, true hermaphroditims and
XX-male (SRY-translocation). Males with XX-karyotype
and partly androgen effects and the diagnosis of true her-
maphroditism and SRY-translocation were reassigned to
subgroup DSD-XY-P-M, because we presumed the pres-
ence of some material of the "Y"-chromosome. The XX-
males (n = 2) with CAH are removed from statistical anal-
ysis due to small numbers, where group comparisons
were conducted.
Table 2: Characteristics of study participants and eligible non-participants from the telephone intake call
Recruited Non-participation Participation
NN  ( % ) N
Study Centers
- Germany:
North 130 17 (13%) 113
East 91 17 (19%) 74
South 119 16 (13%) 103
West 116 19 (16%) 97
- Switzerland 29 3 (10%) 26
- Austria 26 0 (0%) 26
First contact based on
- Medical institutions/physician 439 61 (14%) 378
- Self-help groups 44 4 (9%) 40
- Internet 12 3 (25%) 9
- Other (e.g. friends, school, print media) 16 4 (25%) 12
Sex of rearing in children/recent gender in adults
- Male 144 20 (14%) 124
- Female 367 52 (14%) 315
Age groups
- Newborns 24 1 (4%) 23
- 6 months – 3 years 85 11 (13%) 74
- 4 – 7 years 84 4 (5%) 80
- 8 – 12 years 97 11 (11%) 86
- 13 – 16 years 80 14 (17%) 66
- Adults 141 31 (22%) 110
Time of the presumptive diagnosis
- Prenatal 14 2 (14%) 12
- Perinatal 302 29 (10%) 273
- Postnatal ≤ 1 week 29 0 (0%) 29
- Later 117 12 (10%) 105
- Unknown 49 29 (59%) 20
Inclusion criteria
- Gonadal dysgenesis 81 8 (10%) 73
- Disorders of androgen synthesis 21 2 (10%) 19
- Androgen insensitivity 60 8 (13%) 52
- Congenital adrenal hyperplasia (CAH) 202 28 (14%) 174
- Hypospadia 72 4 (6%) 68
- Other criteria (e.g. micropenis, complex malformation of the urogenital tract) 44 9 (20%) 35
- Suspected diagnosis of DSD 42 15 (36%) 27
- Unknown diagnosis of DSD 1 1 (100%) 0BMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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Subgroup 3 (DSD-XX-C-F)
Individuals with XX-karyotype and without androgen
effects, reared as girls/living as women (n = 3). The group
contains individuals with agonadism, ovarian failure and
complete gonadal dysgenesis. It is debatable to include
women with XX-karyotype and ovarian failure or com-
plete gonadal dysgenesis in the group of DSD. We did so
a priori, because they lack typical male or female sex
development. However, due to small sample size this
group was excluded from statistical analysis on a group
level.
Subgroup 4 (DSD-XY-P-F)
Individuals with XY-karyotype and partial androgen
effects, reared as girls/living as women (n = 96). Included
are the diagnoses pAIS, true hermaphroditism, gonadal
dysgenesis, 17β-HSD, 5alpha-RD, micropenis, severe hyp-
ospadia and individuals with a clinical diagnosis of DSD
fitting the criteria. Subgroup 5 (DSD-XY-C-F): Individuals
with XY-karyotype and without androgen effects, reared as
girls/living as women (n = 39). The group includes indi-
viduals with cAIS, complete gonadal insufficiency and
Swyer-Syndrome.
Subgroup 6 (DSD-XY-P-M)
Individuals with XY-karyotype and partial androgen
effects, reared as boys/living as men (n = 114). Included
are patients with pAIS, true hermaphroditism, gonadal
dysgenesis, 17β-HSD, 5alpha-RD, micropenis, hypospa-
dia and individuals with a clinical diagnosis of DSD fit-
ting the criteria.
For statistical group comparisons we used four subgroups
(1, 4, 5, and 6- the latter including few individuals from
subgroup 2) in the following analyses. Table 3 gives an
overview for these groups including the definition and the
composition with respect to clinical diagnoses and to age
groups. There is evidence that high concentrations of pre-
and postnatal androgens contribute to the development
of male-typical behavior, whereas low levels of androgens
will induce female-typical behavior [6,59,60]. Therefore it
seems important to compare children with DSD with
complete lack and those with partial lack of androgen
effects. In addition, this grouping takes effects of gender-
typical socialization and potential effects of karyotype
into account. Nevertheless, this discussion is not finished
yet. The above classification will be primarily used to test
hypothesis on the influence on diagnoses and related
treatments on all the outcome variables considered in the
study, not least to reduce the multiplicity of hypotheses
even though all future analyses of these data will be
exploratory. In secondary analyses, alternative classifica-
tions will be considered in special problems and then we
shall investigate which classification is best related to the
outcome of interest. First analyses, however, deflate the
expectation to these analyses (e.g., classification and
regression trees or cluster analyses) because the different
classification systems are related to each other and in any
case there will a large unexplained proportion.
2. Assessment of data quality
In order to assess the quality of the data, different aspects
will be considered here: selection bias, heterogeneity,
missing questionnaires, missing items, accordance
between different questionnaires and outliers in the data.
All statistic analyses reported below were performed with
the statistical software package SPSS, version 15. Tests
with p-values below 0.05 were considered as significant.
Due to the study design, all analyses are exploratory.
Selection bias
The selection bias was studied by comparing the individ-
uals who declined participation with those who partici-
pated stratified by certain characteristics (study centre,
access to the study, sex of rearing, age group, time of the
first diagnosis of DSD).
When using the chi-squared test for bivariate analysis,
there were no significant differences between participa-
tion and refusal in relation to study centre, access to the
study and sex of rearing on bivariate analysis (cf. Table 2).
The comparison of the age groups showed a higher rates
of non-participants in adults (p = 0.002). Regarding the
time of first diagnosis of DSD, there were only an
increased proportion of non-participants in those patients
with unknown time of first diagnosis. Type of diagnosis
did not result in different rejection rates with exception of
individuals with severe hypospadia who declined partici-
pation less frequently (p < .05). When checking these
results for mutual confounding of the different factors in
a logistic regression with all factors considered simultane-
ously, then the effect for hypospadia was no longer signif-
icant, indicating confounding effects of age here.
Homo-/heterogeneity between study centers
The different study centers (North, East, South and West
Germany, Switzerland and Austria) were compared in chi-
squared tests for possible heterogeneity of recruited
patients with respect to socio-demographic characteristics
as nationality, religion, size of home town, educational
level and employment (of parents and adults only).
The distribution of age groups and sex of rearing was sim-
ilar across study centers. The proportion of participants
with a mirgational background was about 10% in all cent-
ers. As expected, there were differences between German
study centers in terms of religion (p = 0.004 and 0.001,
respectively, with a smaller proportion of religious people
in the eastern part), reflecting the composition of the cor-
responding populations. Similarly, a larger percentage ofBMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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adult patients was out of job (p = 0.028) and more moth-
ers were working in a full time job (p = 0.002) in the east-
ern part of Germany. In Austria and Switzerland, there
were smaller proportions of participants living in towns
with more than 100,000 inhabitants than in Germany (p
< 0.001) and we found different educational levels of the
mothers in the three countries (0.040). Also between the
four German centers differences have been found in the
educational level with a higher level in the eastern part for
parents of DSD children (p = 0.003 and 0.037, respec-
tively) but a larger proportion of college graduates in the
northern and western part for the adult patients (p =
0.039). As both parents and adults should be of similar
age, that can no longer be explained by differences in the
reference population and it could be an indication of dif-
ferent living conditions of DSD patients in the former
eastern and western part of Germany.
Questionnaire and item non-response for standard instruments
In participants, we calculated the proportion of totally
missing questionnaires and of items not completed on
each standardized instrument. Problems with incomplete
response occurred particularly in children and adoles-
cents, particularly because of missing parental consent or
of tiredness, and we searched in this subgroup for possible
influences on the completion or rejection of single ques-
tionnaires and for non-response in single items.
Table 3: Definition and composition of primary classification groups for the Clinical Evaluation Study
Group 1. DSD-XX 2. DSD-XY-P-F 3. DSD-XY-P-M 4. DSD-XY-C-F
Definition: Girls/women with 46, XX 
DSD and signs of over-
virilization
Girls/women with 46, XY 
DSD and partial signs of 
virilization
Boys/men with 46, XY 
DSD and signs of under-
virilization
Girls/women with 46-XY 
DSD without any signs of 
virilization
Karyotype XX XY+ XY+ XY+
Sex of rearing/recent 
gender
Female Female Male Female
Androgen effects present present present none
Diagnoses contained CAH (172)
True hermaphroditism (1)















diagnosis of DSD (5)
severe hypospadia (53)
gonadal dysgenesis (mixed, 
partial) (25)
pAIS (12)
disorders of AMH (1)




with DSD (cloacal 
extrophy) (1)
micropenis (3)





diagnosis of DSD (9)
cAIS (23)
compl. gonadal dysgenesis 
(14)
gonadal dysgenesis with 
complete female 
phenotype and 45, X/46XY 
(1)
unclassified clinical 
diagnosis of DSD (1)
Age distribution:
Infants < 6 months 8 4 10 1
6 months – 3 years 29 7 36 1
4 – 7 years 29 12 34 5
8 – 12 years 33 24 21 8
13 – 16 years 33 19 7 7
Adults 46 30 13 17
Total n 178 96 121 39
+ incl. mosaics with parts of „Y chromosome" (in some cases chromosome status has not been investigated, in these cases classification results 
according the clinical status)
* despite 46, XX karyotype
Excluded from group comparisons:
46, XX; CAH & male sex of rearing, n = 2
46, XX & without androgen effects (e.g. gonadal insuffiency), n = 3BMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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Table 4 gives an overview on the percentages of missing
response to standardized instruments resulting in loss of
items, of entire sub-scale (which can sometimes be calcu-
lated despite single missing items) and of whole question-
naires.
In children/adolescents the non-response rate to entire
questionnaires ranged from 9.1% for the SDQ and UGDS
to 18.2% for the GII. In parents this rate is always below
2.5% (highest for CBAQ with 2.4%) and no question-
naires are missing in adult participants.
On the average children/adolescents failed to complete
1.7% of items in questionnaires they completed. For ques-
tionnaires administered to parents, the proportion of
items not completed ranged from 0.1% for SDQ to 10.8%
for CBAQ. In adults, the average proportion of items not
completed is 0.6%.
The proportion of missing sub-scale scores on question-
naires completed by children varied from 0% for SDQ to
1% for KINDL. For parents, the proportion of missing
scores ranged from 0.1% for SDQ to 2.9% for CBAQ, and
for questionnaires administered to adults, the proportion
of missing subscale scores varied from 0% for BSI to 1.2%
for FGI.
Overall, the proportions of completely filled question-
naires calculated in relation to all participants, were satis-
factory in most of the questionnaires: in children and
adolescents 193 of 232 (83.2%) answered the KINDL,
120 of 166 (72.3%) the FKSI, 60 of 66 (90.9%) the SDQ
(self-report adolescents only), 53 of 66 (80.3%) the CODI
(adolescents only). However, response rates were insuffi-
cient in some of the questionnaires: 94 of 166 (56.6%)
answered the GII, 92 of 166 (55.4%) the GRQ, and 43 of
66 (65.1%) the UGDS, (adolescents only).
In order to detect possible influences of the age groups,
gender and diagnosis (in the sense of the above classifica-
tion with four groups) in the subgroup of children and
adolescents, we carried out bivariate comparisons (chi-
Table 4: Percentage of missing of entire questionnaires, single items and scores in standardized instrument#.
% non-response to entire questionnaires % missing items in questionnaires completed % missing sub-scale scores
Children/adolescents
- KINDL 10.8 0.8 1.0
- SDQ 9.1 0.0 0.0
- CODI 10.6 0.4 0.3
- FKSI 12.1 1.3 0.7
- GII 18.2 4.0 *
- UGDS 9.1 2.4 *
- GRQ 10.9 3.2 *
- SS-A 10.6 2.1 0.0
- BI-I 9.1 2.2 0.5
Parents
- KINDL 1.3 1.8 1.8
- SDQ 1.7 0.1 0.1
- CBAQ 2.4 10.3 2.9
- PSI 0.0 0.6 0.8
- CHC-SUN 0.3 4.9 7.3
Adults
- SF-36 0.0 0.4 0.1
- BSI 0.0 0.1 0.0
- FGI 0.0 1.4 1.2
- SS-A 0.0 0.7 0.0
- CSQ-8 0.0 0.8 *
- BI-I 0.0 2.8 2.7
BI-1: Body Image Scale, BSI: Brief Symptom Inventory, CBAQ: Child Behavior and Attitudes Questionnaire, CHC-SUN: (Child Health Care – 
Satisfaction, Utilization and Needs, CODI: Coping questionnaire for children and adolescents, CSQ-8: Client satisfaction questionnaire, DSD: 
Disorder of Sex Development, FGI: Questionnaire of Gender Identity, FKSI: Frankfurt children's self-concept inventory, GRQ: Gender Role 
Questionnaire, GII: Gender Identity Interview, KINDL: Questionnaire for measuring health-related quality of life in children and adolescents, PSI: 
Parenting Stress Index, SDQ: Strengths and Health Questionnaire, SF-36: Health Survey, UGDS: Utrecht Gender Dysphoria Scale
* = not applicable
# The percentages for items and for subscale scores are averaged over all items or subscale scores of the questionnaire. The calculations for these 
two columns do not include those persons who omitted the entire questionnaire (cf. second column).BMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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squared tests) for each of these factors and multivariate
comparisons (logistic regression) for mutual adjusted
comparisons.
With respect to the percentage of completely missing
questionnaires, only the age group showed significant
influences (both in the unadjusted and adjusted compar-
isons) for the KINDL, the FKSI, the GII and the GRQ,
where the younger group (age 4 – 7) hat the largest pro-
portion if missing questionnaires. Related to the number
of missing items in the available questionnaires, there was
only a significant effect of age for the GII, where the
younger group (age 4–7) had less missings (both adjusted
and unadjusted). An influence of the diagnosis was seen
in the unadjusted test for UGDS (with largest percentage
of missings for DSD-XY-P-F) but the significance disap-
peared in the adjusted comparison, so that it could be an
indirect effect of gender and age.
Completeness of medical data
The medical data questionnaire answered by a medical
doctor was available for all participants. The self con-
structed DSD questionnaire was answered by the parents
and by the adult participants in all cases, six adolescents
(9%) did not respond to this questionnaire. Table 5 gives
an overview of missing items as average over groups of
items.
In adolescents, some questions showed poorer response
rates than others. The highest average proportion of miss-
ing values was 9.1% in the area of diagnostic procedures
and 7.7% in the area of sexuality. In the parent DSD-ques-
tionnaires, most missing values concerned treatment
(6.7%), and in the adult DSD-questionnaires, questions
about sexuality had the highest rate of missing values
(10%).
In the medical questionnaire, we found missing values in
some areas – the proportion varied between 1.3% for
questions about pregnancy and birth and 10% for ques-
tions about actual findings.
Discrepancies between the self-administered DSD questionnaires 
and the medical questionnaire
Some items were recorded both in the medical question-
naire (filled in by the physicians) and in the DSD ques-
tionnaires (completed by the patients or their parents).
The consistency of related items from different instru-
ments is investigated in cross-classifications of the corre-
sponding items.
A comparison of the answers showed substantial differ-
ences in items related to current height and weight, data
on pregnancy and birth, data on suspected diagnosis and
diagnosis, data on karyotype and data on surgical treat-
ments and hormone therapy. A selection of deviating data
is represented in Table 6.
Outliers in psychological outcome
Another aspect of data quality in the study is the occur-
rence of outliers, here particularly considered in the psy-
chological outcomes. We checked outliers in all sub-scales
both in the total study population and in subgroups for
age and for diagnosis using an outlier definition as con-
ventional for box plot presentations: an outlier is a value
which is more than 1.5 inter-quartile range above/below
the upper/lower quartile of that variable.
The rates are similar across age groups and also across
diagnosis groups (not shown here in detail). There is no
age group or diagnosis group with a relevant increased
percentage of outliers. The proportions vary slightly
among different psychological constructs. Table 7
presents the number (as range over the different subscales
of an instrument) and percentage (averaged over all sub-
scales) of outliers separately for children/adolescents, par-
ents and adult patients.
A check of the individual data showed that outliers in dif-
ferent outcomes are generally not caused by the same
individuals. For example, among 44 children and adoles-
cents with outliers in anyone instrument only seven had
outliers in two different questionnaires. Among 68 par-
Table 5: Percentage of missing items in DSD-questionnaires, averaged over groups of items
Topic % missing in
DSD quest. for adolescents
% missing in
DSD quest. for parents
% missing in DSD quest. for 
adults
% missing in medical data 
questionnaire
Person, family, social 
contacts
5.0 2.5 0.7 *
Pregnancy, birth * 0.3 1.0 1.3
Development of child * 5.4 * *
Diagnostics 9.1 3.8 2.4 4.2
Treatments 4.2 6.7 5.4 5.2
Experiences 5.5 5.4 0.5 *
Sexuality 7.8 * 10.0 *
Actual findings * * * 10.3
*' = not applicableBMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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Current height (adolescents/adults, deviation > 5 cm) 3 1.8
Weight (adolescents/adults, deviation > 5 kg 84 . 7
Mode of delivery 92 . 0
Medication during pregnancy 43 9.8
Week of gestation at birth 87 19.8
Length at birth, deviation > 4 cm 81 . 8
Birth weight, deviation > 400 g 61 . 4
Age at the time of presumptive diagnosis
- deviation ≥ 3 months 43 9.8
- deviation ≥ 6 months 34 7.8
- deviation ≥ 12 months 19 4.4
- deviation ≥ 24 months 13 3.0
- deviation ≥ 48 months 71 . 6
Signs and symptoms leading to the suspected diagnosis of DSD (varying for different symptoms) 2 – 89 0.5 – 20.3
Karyotype 36 8.2
Current diagnosis 48 10.9
Number of operations (by adolescents) 13 21.0
Surgical treatment 15 3.4
Type of the surgical treatment (varying for treatments) 3 – 67 0.7 – 15.3
Previous hormone therapy 96 21.9
Current hormone therapy 35 7.8
Table 7: Number and percentage of outliers in standardized instruments
Questionnaire Number of outliers in sub-scales from – to % (average over all sub-scales)
Children/Adolescents
- KINDL 0 – 9 1.4
- SDQ 0 – 4 2.1
- CODI 0 – 1 0.3
- FKSI 0 – 2 0.5
- GII 9 – 17 7.9
- UGDS 2 3.0
- GRQ 0 0.0
Parents
- KINDL 2 – 11 2.6
- SDQ 0 – 4 1.1
- CBAQ 1 – 2 0.9
- PSI 0 – 17 2.1
Adults
- SF-36 0 – 25 4.8
- BSI 0 – 4 0.7
- FGI 0 – 11 7.1
BI-1: Body Image Scale, BSI: Brief Symptom Inventory, CBAQ: Child Behavior and Attitudes Questionnaire, CHC-SUN: (Child Health Care – 
Satisfaction, Utilization and Needs, CODI: Coping questionnaire for children and adolescents, CSQ-8: Client satisfaction questionnaire, DSD: 
Disorder of Sex Development, FGI: Questionnaire of Gender Identity, FKSI: Frankfurt children's self-concept inventory, GRQ: Gender Role 
Questionnaire, GII: Gender Identity Interview, KINDL: Questionnaire for measuring health-related quality of life in children and adolescents, PSI: 
Parenting Stress Index, SDQ: Strengths and Health Questionnaire, SF-36: Health Survey, UGDS: Utrecht Gender Dysphoria ScaleBMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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ents with outliers, only ten had outliers in two question-
naires and five in three different questionnaires; among
49 adults with outliers, six had outliers in two different
questionnaires and two in three different questionnaires.
Also outliers in more than sub-scale of an instrument were
rare.
Discussion
The Clinical Evaluation Study of the German DSD net-
work presented here is the largest and most comprehen-
sive study on quality of life, psychosexual development,
treatment satisfaction, coping, and related problems in
persons with DSD available at present. In a re-iterative
consensus process the study group has made important
decisions about ways to classify individuals in clinically
appropriate groups to allow analysis on a group level. The
Consensus statement of the ESPE/LWSPE was instrumen-
tal in this process. We decided to combine the principle of
a generic classification based on karyotype and type of
genetic disorder with the fact in which gender role
(female/male) the individual is being raised (in children)
and actually lives. Alternative proposals included:
1. Classification by gender, arguing with gender as a social
construction. We felt that such a classification would com-
bine individuals with very different hormone exposure
and treatment experiences, i.e. those with CAH and cAIS,
both living as women. However, for some aspects of anal-
ysis, for example differences in social participation,
researchers may use such a simple grouping in certain cir-
cumstances.
2. Classification by phenotype of genitalia (defined e.g.
according to Prader classification). The underlying
hypothesis of this approach is that the degree of genital
virilization may be used as an indicator for prenatal
androgen effects on brain development [20,61-63]. There
are several reasons why we decided not to follow the
grouping according to Prader-stage: The first and most
important reason is, that there is no scientific evidence for
a direct relationship between the degree of genital viriliza-
tion and the masculinization of the brain [64,65].
Another reason arises from our poor data quality on
Prader-stage, both at birth/time of diagnosis (17.1%
unknown or missing) and currently (20.0% unknown or
missing). Data quality is limited not only because of miss-
ing data, but also because of the retrospective collection of
data, coming from patient's records rarely completed by
DSD-specialists. As a result, we found some implausible
data such as a Prader-stage 3 in individuals with cAIS.
Therefore, we chose the above classification in 4 sub-
groups. We acknowledge the fact that the classification
may be suitable for our purposes with a focus on psycho-
social outcomes such as psychosexual development,
social participation, psychological well-being and health
related quality of life. A large body of literature on the
impact of chronic conditions in childhood has shown
that the psychosocial aspects of patient care, family adap-
tation, coping strategies and social support are of greater
importance than the individual diagnosis [66]. This does
by no means challenge other classification systems that
may be better suited for example for treatment outcomes,
biological studies on pathophysiology, or genetic studies.
The classification scheme combining the karyotype,
androgen effects and actual gender role has certain advan-
tages: (1) it allows inclusion of individuals with extremely
rare conditions, so that their information can be analyzed
within a meaningful comparison of individuals with sim-
ilar conditions; (2) it allows individuals with tentative
diagnoses to participate if they met the generic inclusion
criteria for DSD; (3) it takes into consideration the effects
of androgens on the developing brain which are thought
to affect gender-typical behavior and gender identity; and
(4) it includes social aspects of living with a chronic con-
dition.
Although the study has been well prepared in several steps
assuring an adequate study design, appropriate instru-
ments, implementing standard operating procedures and
safeguarding data protection, several limitations have to
be noted.
Representativeness
The study may be not completely representative for indi-
viduals with DSD. We attempted to evaluate possible
selection bias by recording some baseline data of non-par-
ticipants and found only a few characteristics overrepre-
sented in those who had declined participation,
indicating only mild effects of but not excluding selection
bias. We explicitly found an influence of age with adult
persons being less willed to participate. Presumably, their
commitment to the attending physicians inviting them to
participate in the study is less pronounced compared to
younger age-groups.
Other factors not reflected in our data come from the psy-
chologists conducting the interviews. They encountered
several problems in recruiting participants for the study:
(1) Some physicians taking care of individuals with DSD
did not wish to cooperate with the network at all, particu-
larly in clinics for patients with CAH. In an inquiry in
2005 among medical cooperation partners within the net-
work, the clinicians stated, that they would not inform
approximately 10% of their patients. Specific reasons
included: 1. no disclosure about the diagnosis, 2. unwill-
ingness to accept a given diagnosis as a form of "DSD/BMC Public Health 2009, 9:110 http://www.biomedcentral.com/1471-2458/9/110
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Intersexuality", or 3. concerns about the psychological
impact caused by the interviews.
(2) Another problem of recruitment emerged in respect to
newborns with DSD age 0 to 6 months and individuals
with a new diagnosis of a DSD within the last 6 months.
These two groups turned out to be extremely burdened by
the diagnostic process and coping with a DSD-diagnosis,
and were not open to participate in a study. Thus just the
two cohorts with intended follow-up are very small (23
newborns and 3 patients with a new diagnosis, responded
to the follow-up interview), so that the longitudinal part
of the study focused on changes in the outcome cannot
seriously be analyzed.
Generally, we cannot exclude that persons with particu-
larly poor experience in their medical history are less pre-
sented in the study. Nevertheless, we hope that the broad
inclusion of patients from medical centers, and self-iden-
tified members of self-help groups and the internet
reduced the bias. Even the latter groups had to agree to
consent to release a physician from the professional
secrecy and collection of medical data. This excludes indi-
viduals not in contact with the medical system.
Homogeneity/heterogeneity of study centers
As described above, the study centers are homogeneous
with respect to age, gender and nationality of their
patients. The observed heterogeneity regarding religion
and unemployment just reflects the corresponding differ-
ences in the population in general, and is not specific for
persons with DSD or their families. That might be not the
case for the educational level with different distributions
for adult patients and the parents of children with DSD
which could be a hint for specific conditions in different
regions.
Thus, particularly analyses for quality of live, which is
often related to the educational level, and with respect to
access and satisfaction with patient care, should be con-
ducted including the study centre as a co-factor in order to
avoid a potential confounding for certain socio-demo-
graphic and health care related characteristics.
Missing response to entire questionnaires or to items and 
subscales
The rates of non-response to entire questionnaires is gen-
erally low, indicating that the opportunity to answer the
questionnaires with an interviewer present and to ask
questions was successful to keep missing items as small as
possible. The problem was most prominent in children,
because of missings due to lack of parental consent for
some or all children questionnaires. The percentage of
missing items is acceptable – also because of the technical
interim check of instruments combined with some reduc-
tion of problematic items. The remaining problems in
some single items are due to the very intimate nature of
the study and were hardly to prevent.
Consistency of medical data
Another limitation of the study – related to the fact that it
is a purely observational study – is that the medical data
coming from physicians on the basis of their medical
records may be not up-to-date at the time of the request to
answer the questionnaire. That explains, e.g., the disagree-
ment in the data for body height or body weight between
questionnaires answered by patients and those from the
physicians. Furthermore, the large proportion of physi-
cians (about 80%) with only one or two patients included
in the study indicates that at least some of them are not
very experienced in the field of DSD, which may have neg-
ative effects on the data quality. Indeed, more detailed
analyses, presented here, revealed also conflicts between
the diagnoses stated and the accompanying information
for a few patients. The only resort from this problem
would have been the integration of a medical examina-
tion and possibly further testing by experienced endo-
crinologists. Aside from the enormous costs for such a
study, we were anxious that this may have prevented even
more individuals and families to participate due to the
sensitive nature of the condition. The study design and
recruitment allowed us to recruit the planned number of
persons with DSD. The parallel questioning of attending
physicians and the individuals (or parents) assured at
least some degree of validation of the diagnoses and treat-
ment related data. The remaining uncertainty has to be
addressed in the ongoing main analyses of the study by
sensitivity analyses with different choices for suspect diag-
noses.
Thus summarizing, the study has good chances to reveal
new insight in the quality of life, gender identity, treat-
ment satisfaction and further related outcome in persons
with DSD and in its relevant impact factors. This will be
the concern of future publications based on the present
paper. The problems mentioned are to some degree una-
voidable in studies in such a highly sensitive field. For the
reasons discussed and with a careful interpretation of the
results, they should not stress the credibility of the study
results.
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